Latest news with #Balaxi
India.com
a day ago
- Business
- India.com
THIS company stock surges over 19 percent after..., it outpaced the performance of...
सेफ इंवेस्टमेंट भी जरूरी New Delhi: Shares of Balaxi Pharmaceuticals, a Hyderabad-based pharmaceutical company, witnessed a significant surge on Monday, August 11, 2025. The stock, which belongs to the small-cap category, surged as much as 19 per cent on the National Stock Exchange. This surge was particularly noteworthy as it outpaced the performance of the equity benchmark indices Sensex and Nifty, which also started the trading session in positive territory. The positive start was attributed to fresh foreign fund inflows and a rally in the US markets, making Balaxi's surge a standout event in the market. The stock opened in the green at Rs 49, up from its previous close of Rs 43.67 on the BSE. It further touched the intraday high of Rs 52, a gain of 19.07 per cent from the last close. As of last seen, the stock was trading at Rs 49.74. It's important to note that the stock's 52-week high is Rs 127.45, indicating its potential for growth, while the 52-week low is Rs 42.56, reflecting its stability. The company's market cap is Rs 271.95 crore, further underlining its long-term performance. Technically, the stock is currently trading higher than the 5-day and 20-day moving averages, which are short-term indicators of the stock's recent performance. However, it is trading lower than the 50-day, 100-day, and 200-day moving averages, which are longer-term indicators. This suggests that while the stock has shown recent strength, it is still facing challenges in the medium to long term. Quarterly Results Despite a challenging quarter, the company demonstrated resilience, reporting a net profit of Rs 0.19 crore in the April-June quarter of the financial year 2025-26, a decrease from Rs 1.38 crore in the same quarter a year ago. According to the information shared, the company's revenue from operations stood at Rs 16.71 crore in the quarter under concern. This is down by 12.18 per cent from Rs 19.03 crore in the same quarter in the previous year. Also, EBITDA stands at Rs 1.00 crore in June 2025 down 57.63 per cent from Rs 2.36 crore in June 2024.
Mint
09-06-2025
- Business
- Mint
Small-cap stock under ₹100 jumps almost 11% as company shares expansion plans. Details here
Shares of Balaxi Pharmaceuticals surged over 10 percent on Monday, June 9, after the company announced its strategic expansion roadmap along with its financial results for the fourth quarter and full year of FY25. The small-cap stock, which trades below ₹ 100, jumped as much as 10.7 percent in intra-day trade to reach a high of ₹ 57.5. The rally came on the back of Balaxi's aggressive plans to enter new markets, strengthen its supply chain through backward integration, and capitalize on its existing presence in frontier markets. Balaxi outlined an ambitious growth strategy aimed at deepening its presence in current markets and entering new geographies. Between 2021 and 2024, the company expanded into regions such as Honduras, El Salvador, Nicaragua, and the Central African Republic by leveraging physical infrastructure and offering a wide range of products to meet consumer demand. Building on this foundation, the company now plans to scale operations further by entering additional Latin American countries, Southeast Asia, and the Commonwealth of Independent States (CIS). This expansion will follow Balaxi's proven business model, which emphasizes differentiation and rapid scalability. A major component of the company's strategy for FY25 and beyond is the backward integration of its supply chain. Balaxi is in the final stages of operationalizing its first pharmaceutical formulation manufacturing facility in Jadcherla, Hyderabad. The plant has completed construction and installation, and Operational Qualification (OQ) and validation processes are underway, expected to be completed by the end of June 2025. Once functional, the facility will enable Balaxi to improve quality control, reduce costs, and support its medium-to-long-term growth plans by ensuring greater self-reliance in production. Balaxi's financial performance for FY25 reflected a strong turnaround, with the company posting a net profit of ₹ 25 crore, a sharp recovery from a net loss of ₹ 2.39 crore in FY24. Annual revenue rose 21 percent to ₹ 292.5 crore from ₹ 241.3 crore in the previous fiscal. However, rising costs weighed on profitability, with EBITDA falling 24 percent year-on-year to ₹ 33.5 crore. EBITDA margins also declined to 11.5 percent from 18.3 percent in FY24, reflecting cost pressures primarily due to inflation, administrative expenses, and employee-related costs. In the March 2025 quarter, net profit fell 21 percent to ₹ 8.64 crore from ₹ 10.9 crore a year earlier. Nonetheless, revenue during the quarter rose by 27.5 percent to ₹ 76.3 crore, indicating healthy topline growth. Operationally, EBITDA dropped 7 percent to ₹ 10.86 crore, and the EBITDA margin contracted to 14.2 percent from 19.5 percent in the same quarter of the previous year. The company attributed the full-year growth to its enhanced execution capabilities and a shift in go-to-market strategy, particularly through newer sales channels such as institutional and hospital tenders. Balaxi also reported 85 new product registrations during the year, expanding its portfolio to 915 products across seven countries in Africa and Latin America. The management stated that this robust pipeline, combined with focused market penetration, will support continued revenue growth and market share expansion. While the June 9 rally brought some relief to shareholders, Balaxi's stock has had a turbulent ride over the past year. Despite the recent gains, the stock is still down over 54 percent on a year-on-year basis. However, it has shown signs of recovery in recent months. In June so far, the stock has climbed 14 percent, following a 9.4 percent fall in May and a 13.7 percent decline in April. Notably, it had risen 20 percent in March, ending a seven-month losing streak that spanned from August 2024 to February 2025.
Mint
09-06-2025
- Business
- Mint
Small-cap stock under ₹100 jumps almost 11% as company shares expansion plans. Details here
Shares of Balaxi Pharmaceuticals surged over 10 percent on Monday, June 9, after the company announced its strategic expansion roadmap along with its financial results for the fourth quarter and full year of FY25. The small-cap stock, which trades below ₹ 100, jumped as much as 10.7 percent in intra-day trade to reach a high of ₹ 57.5. The rally came on the back of Balaxi's aggressive plans to enter new markets, strengthen its supply chain through backward integration, and capitalize on its existing presence in frontier markets. Balaxi outlined an ambitious growth strategy aimed at deepening its presence in current markets and entering new geographies. Between 2021 and 2024, the company expanded into regions such as Honduras, El Salvador, Nicaragua, and the Central African Republic by leveraging physical infrastructure and offering a wide range of products to meet consumer demand. Building on this foundation, the company now plans to scale operations further by entering additional Latin American countries, Southeast Asia, and the Commonwealth of Independent States (CIS). This expansion will follow Balaxi's proven business model, which emphasizes differentiation and rapid scalability. A major component of the company's strategy for FY25 and beyond is the backward integration of its supply chain. Balaxi is in the final stages of operationalizing its first pharmaceutical formulation manufacturing facility in Jadcherla, Hyderabad. The plant has completed construction and installation, and Operational Qualification (OQ) and validation processes are underway, expected to be completed by the end of June 2025. Once functional, the facility will enable Balaxi to improve quality control, reduce costs, and support its medium-to-long-term growth plans by ensuring greater self-reliance in production. Balaxi's financial performance for FY25 reflected a strong turnaround, with the company posting a net profit of ₹ 25 crore, a sharp recovery from a net loss of ₹ 2.39 crore in FY24. Annual revenue rose 21 percent to ₹ 292.5 crore from ₹ 241.3 crore in the previous fiscal. However, rising costs weighed on profitability, with EBITDA falling 24 percent year-on-year to ₹ 33.5 crore. EBITDA margins also declined to 11.5 percent from 18.3 percent in FY24, reflecting cost pressures primarily due to inflation, administrative expenses, and employee-related costs. In the March 2025 quarter, net profit fell 21 percent to ₹ 8.64 crore from ₹ 10.9 crore a year earlier. Nonetheless, revenue during the quarter rose by 27.5 percent to ₹ 76.3 crore, indicating healthy topline growth. Operationally, EBITDA dropped 7 percent to ₹ 10.86 crore, and the EBITDA margin contracted to 14.2 percent from 19.5 percent in the same quarter of the previous year. The company attributed the full-year growth to its enhanced execution capabilities and a shift in go-to-market strategy, particularly through newer sales channels such as institutional and hospital tenders. Balaxi also reported 85 new product registrations during the year, expanding its portfolio to 915 products across seven countries in Africa and Latin America. The management stated that this robust pipeline, combined with focused market penetration, will support continued revenue growth and market share expansion. While the June 9 rally brought some relief to shareholders, Balaxi's stock has had a turbulent ride over the past year. Despite the recent gains, the stock is still down over 54 percent on a year-on-year basis. However, it has shown signs of recovery in recent months. In June so far, the stock has climbed 14 percent, following a 9.4 percent fall in May and a 13.7 percent decline in April. Notably, it had risen 20 percent in March, ending a seven-month losing streak that spanned from August 2024 to February 2025. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
